Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Change in Accured Expenses (2016 - 2025)

Angiodynamics (ANGO) has disclosed Change in Accured Expenses for 16 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 57.48% year-over-year to $3.2 million, compared with a TTM value of -$15.9 million through Nov 2025, down 175.69%, and an annual FY2025 reading of -$15.9 million, down 157.67% over the prior year.
  • Change in Accured Expenses was $3.2 million for Q4 2025 at Angiodynamics, up from -$10.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $17.7 million in Q1 2024 and bottomed at -$16.5 million in Q3 2023.
  • Average Change in Accured Expenses over 5 years is $945550.0, with a median of $2.3 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses tumbled 446.88% in 2022, then skyrocketed 515.14% in 2024.
  • Year by year, Change in Accured Expenses stood at $1.8 million in 2021, then surged by 235.72% to $6.1 million in 2022, then skyrocketed by 153.34% to $15.6 million in 2023, then plummeted by 51.97% to $7.5 million in 2024, then crashed by 57.48% to $3.2 million in 2025.
  • Business Quant data shows Change in Accured Expenses for ANGO at $3.2 million in Q4 2025, -$10.7 million in Q3 2025, and $2.6 million in Q2 2025.